Who is sponsoring NCT06742515?

NCT06742515 is sponsored by First Affiliated Hospital of Zhejiang University.

What drugs are being tested in NCT06742515?

Interventions in NCT06742515: Blinatumomab plus Reduced-dose Chemotherapy.

What condition does NCT06742515 study?

NCT06742515 studies Precursor B-Cell Acute Lymphoblastic Leukemia.

Is NCT06742515 still recruiting?

NCT06742515 is currently recruiting now. Last updated 19 December 2024.

Last reviewed 2024-12-19 · How we verify

NCT06742515

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Blinatumomab Plus Reduced-dose Chemotherapy in Treating B-ALL

Recruiting now Phase 2 Last updated 19 December 2024

What this trial tests

Phase 2 trial testing Blinatumomab plus Reduced-dose Chemotherapy in Precursor B-Cell Acute Lymphoblastic Leukemia in 20 participants. Currently enrolling.

Timeline

17 October 2024

Primary endpoint
1 October 2026

31 August 2028

Quick facts

Lead sponsor	First Affiliated Hospital of Zhejiang University
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	17 October 2024
Primary completion	1 October 2026
Estimated completion	31 August 2028
Sites	1 location across China

Drugs / interventions tested

Blinatumomab plus Reduced-dose Chemotherapy — full drug profile →

Conditions studied

Precursor B-Cell Acute Lymphoblastic Leukemia — all drugs for Precursor B-Cell Acute Lymphoblastic Leukemia →

Sponsor

First Affiliated Hospital of Zhejiang University

Who can join

Adults 15 to 59, any sex, with Precursor B-Cell Acute Lymphoblastic Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Precursor B cell acute lymphoblastic leukemia (B-ALL) is an aggressive type of leukemia, with high relapse rate and poor long term survival in adults. Traditional treatment regimens mainly include chemotherapy and hematopoietic stem cell transplantation. In the past decade, with the application of molecular targeted drugs and immunotherapy, the survival of B-ALL patients has significantly improved. In this study，we propose a treatment approach that combines Blinatumomab and Reduced-dose Chemotherapy in B-ALL adults. Our study aims to answer the safety and efficacy of this treatment regimen, and further improve the survival for those participants.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

B-Cell Lymphoma 2 Inhibition in Acute Lymphoblastic Leukemia: Mechanisms, Resistance, and Emerging Combinations With Venetoclax.
Hanbali A, Kotb A, Saleh M. · · 2025 · cited 1× · PMID 40904937 · DOI 10.14740/jh2092

Verify or expand the search:

Other trials of Blinatumomab plus Reduced-dose Chemotherapy

Trials testing the same drug.

NCT06930105 — Impact of Low-intensity Chemotherapy Combined With Short-course Blinatumomab on Allo-HSCT in Adults With Ph- B-ALL · Phase 2 · not yet recruiting

Other recruiting trials for Precursor B-Cell Acute Lymphoblastic Leukemia

Currently open trials in the same condition.

NCT04629729 — FT819 in Subjects With B-cell Malignancies · Phase 1 · active not recruiting

Other First Affiliated Hospital of Zhejiang University trials

Trials by the same sponsor.

NCT07537192 — Inulin-Spirulina Co-intervention for Insomnia Disorder · NA · not yet recruiting
NCT07510867 — 18F-FAPI PET/CT and MRI in Gastric Cancer · not yet recruiting
NCT07589647 — Research on the Efficacy and Safety of Targeted Suprachiasmatic Nucleus Electrical Stimulation for Improving Metabolic D · NA · recruiting
NCT07525765 — AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer · recruiting
NCT07468162 — Characteristic Electroencephalogram of General Anesthesia · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06742515 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital of Zhejiang University
Last refreshed: 19 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06742515.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing